Sarkomy Kostej Magkih Tkanej i Opuholi Kozi
Insulin-like growth factors and their transfer protein in the blood of patients with primary and recurrent soft tissue sarcomas
Soft tissue sarcomas (STS) are rare diseases but their characteristic tendency for recurrence and high mortality dictate the need for the search for prognostic biomarkers for identification of patients with the risk of recurrence. In this context, the system of insulin-like growth factors (IGF) and their insulin-like growth factor-binding proteins (IGFBP) is of interest because it was shown that disruption of the IGF system regulation leads to cancer cell proliferation and migration and chemotherapy resistance. The study objective is to investigate the levels of the IGF system components in
Read MoreEvaluation of the effectiveness of the use of the double mobility in oncological hip replacement
Currently, the achievements of oncological hip replacement play an important role in the treatment and rehabilitation of patients with a tumor lesion of the proximal femur. To evaluate the effectiveness of the use of the acetabulum component with double mobility in oncological hip replacement. Our prospective study included 108 patients operated in the Department of Bone Oncology of the R.R. Vreden National Medical Research Center of Traumatology and Orthopedics, Ministry of Health of Russia for a tumor lesion of the proximal femur in the period from 2014 to 2019. There were 65 (60.2 %) wom
Read MoreRESULTS OF NEOADJUVANT DENOSUMAB IN GIANT CELL TUMOR OF THE BONE DEPENDING OF THE TUMOR LOCATION AND THE SURGICAL GRADE
The standard treatment for giant-cell tumors of the bone includes radical surgery. However, specific anatomical location of the tumor and/or its spread may hinder its complete excision or result in poor functional outcomes. Currently, combination treatment that includes preoperative denosumab and surgery is preferable. It saves patients’ lives and improves their quality of life. Reduction of local recurrence rate by combination therapy for giant-cell tumors of the bone is being actively studied now. To analyze treatment outcomes of patients with giant-cell tumors of the bone, includin
Read MoreCOMBINED TREATMENT OF GIANT CELL BONE TUMOR
Curettage is recommended for the treatment of Campanacci stages 1–2 giant cell tumor of bone (GCTB) in the extremities, pelvis, sacrum, and spine, without preoperative denosumab treatment. In the distal femur, bone chips and plate fixation are utilized to reduce damage to the subchondral bone and prevent pathological fracture, respectively. For local recurrence, re-curettage may be utilized when feasible. En bloc resection is an option for very aggressive Campanacci stage 3 GCTB in the extremities, pelvis, sacrum, and spine, combined with 1–3 doses of preoperative denosumab trea
Read MoreSURGICAL TREATMENT OF PATIENTS WITH METASTATIC BONE LESIONS DURING THE COVID-19 PANDEMIC
In March 2020, the World Health Organization announced the COVID-19 as a pandemic. The emergence and spread of the new infection hit most healthcare systems globally. The pandemic caused temporary restrictions for elective medical care, which affected many patients at risk, including cancer patients, since some hospitals were closed for quarantine. Deferred pharmacotherapy, radiotherapy, and surgery in these individuals might have resulted in disease progression and even death. In this situation, healthcare professionals had to quickly adjust the manage ment strategy for cancer patients and
Read More